KDR and ovarian carcinoma: Our research detailedly reveals that PS VII may hinder the binding of ECM1 to VEGFR2 and inhibit the FAK/AKT/GSK3β signaling pathway in ovarian cancer PARP inhibitor-resistant cells, affecting glycolysis, angiogenesis, and other functions, ultimately elucidating the specific mechanism by which it improves resistance.